A 3-year-old unvaccinated child from rural India presents to the emergency department with a 2-day history of fever, severe headache, neck stiffness, and photophobia. CSF analysis shows pleocytosis (WBC 450/μL, predominantly neutrophils), elevated protein (120 mg/dL), and normal glucose (45 mg/dL). Gram stain of CSF reveals gram-negative coccobacilli. What is the most appropriate immediate next step in management?

Explanation

## Clinical Diagnosis **Key Point:** The CSF profile (pleocytosis with neutrophil predominance, elevated protein, normal glucose) combined with gram-negative coccobacilli on Gram stain is pathognomonic for bacterial meningitis caused by *Haemophilus influenzae*. ## Management Algorithm ```mermaid flowchart TD A[Suspected bacterial meningitis<br/>+ Gram-negative coccobacilli on CSF Gram stain]:::outcome --> B{Organism identified?}:::decision B -->|Yes: H. influenzae| C[Blood cultures already done<br/>during LP]:::action C --> D[Start empiric therapy<br/>immediately]:::action D --> E[Ceftriaxone 2g IV Q6H<br/>or Cefotaxime 2g IV Q4-6H]:::action E --> F[Culture & sensitivity<br/>to guide de-escalation]:::action F --> G[Continue for 7-10 days]:::outcome ``` ## Why Ceftriaxone is First-Line | Antibiotic | Spectrum | CSF Penetration | Resistance Pattern | Status | |---|---|---|---|---| | **Ceftriaxone** | 3rd-gen cephalosporin; covers H. influenzae, N. meningitidis, S. pneumoniae | Excellent (15–20% of serum) | Covers β-lactamase producers and ampicillin-resistant strains | **Gold standard** | | Ampicillin | Covers H. influenzae (susceptible strains only) | Moderate | Does NOT cover β-lactamase–producing H. influenzae (30–40% prevalence in India) | **Inadequate** | | Chloramphenicol | Older agent; H. influenzae coverage | Good CSF penetration | Resistance emerging; hepatotoxicity risk | **Outdated** | | Fluoroquinolones | Broad spectrum | Moderate CSF penetration | Not recommended as monotherapy for meningitis | **Adjunctive only** | **High-Yield:** In India, β-lactamase–producing *H. influenzae* (BLPHI) prevalence is 30–40%, making ampicillin unreliable. Ceftriaxone covers both β-lactamase producers and ampicillin-resistant non-β-lactamase producers (BLNAR). ## Timing of Antibiotics **Clinical Pearl:** Blood cultures should be drawn *before* LP if possible, but **antibiotics must NOT be delayed** waiting for culture results or imaging. Delay of even 30 minutes increases mortality and morbidity in meningitis. **Key Point:** Dexamethasone (0.15 mg/kg IV Q6H for 4 days) is given *concurrently* with or *just before* the first antibiotic dose, not instead of antibiotics or after a 24-hour observation period. ## Vaccination Status **Mnemonic:** **Hib-PRP-OMP** = Haemophilus influenzae type b polyribosyl ribitol phosphate conjugate vaccine. This child is unvaccinated, explaining the invasive disease. Post-recovery, Hib vaccination is indicated. [cite:Harrison 21e Ch 173]